Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

MHRA Website

[redacted]

Our Ref: **FOI2025/01340**

28 January 2026

Dea[redacted]

Thank you for your Freedom of Information (FoI) request received on 30 December. You wrote:

> *Please provide the following under the Freedom of Information Act:*
> *1. All internally-held epidemiological analyses (published or unpublished) relating to thyroid dysfunction following any COVID-19 vaccine.*
> *2. All Yellow Card signal assessments conducted for:*
>
> * *hypothyroidism*
> * *thyroiditis*
> * *autoimmune thyroid disease*
> * *vaccine-induced endocrine dysfunction*
>
> *1.*
> *2. Internal risk assessments relating to endocrine adverse events.*
> *3. Any correspondence between MHRA and DHSC discussing thyroid-related vaccine injury signals.*
> *4. Copies of internal deliberations where MHRA decided not to list thyroid conditions as adverse reactions in SmPC documentation.*
> *5. Any document that evaluates the adequacy of current post-marketing surveillance for endocrine disorders.*

MHRA Response

The Agency has completed its search for the information you have requested and we are able to confirm that we do hold some of the information you have requested.

Please note that part of your request has not been provided as we require clarification of the information you seek. I will address your 6 requests point by point, explaining why and how clarification is required where appropriate.

1. You first request "*All internally-held epidemiological analyses (published or unpublished) relating to thyroid dysfunction following any COVID-19 vaccine."* We can confirm that the MHRA does hold this information, which is available to view via the following link: [https://products.mhra.gov.uk/].

Information regarding all Covid-19 vaccines authorised for use in the United Kingdom are listed online by the MHRA at the following address [https://products.mhra.gov.uk/]. If the filter is then set to 'Public Assessment Report' (PAR), a pdf report will appear for each of these vaccines. These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of the medicine, providing insights into the clinical data reviewed and how the assessment outcome was reached. All epidemiological analyses for the UK-authorised Covid-19 vaccines have been published and are available to view on this website.

2. You go on to request *"All Yellow Card signal assessments conducted for hypothyroidism, thyroiditis, autoimmune thyroid disease and vaccine-induced endocrine dysfunction."* We can confirm that the MHRA does hold this information, which is available to view via the following link: [https://yellowcard.mhra.gov.uk/idaps].

   The MHRA maintains interactive drug analysis profiles (iDAPs) for the Covid-19 vaccines it has authorised for use in the United Kingdom. Each iDAP contains a complete listing of all suspected adverse reactions that have been reported to the MHRA via the Yellow Card scheme. This includes all reports received from healthcare professionals, members of the public, and pharmaceutical companies. The iDAP provided on this website are regularly updated. Please be aware, however, that if you have reported a suspected adverse drug reaction it may not immediately appear on this website. There is a time delay of around one month from receipt of a report to it appearing in the summary.

   When reviewing the data within an iDAP it is important to do so in the context of the essential guidance at the bottom of the report to ensure that you do not misinterpret the data.

3. You then request *"Internal risk assessments relating to endocrine adverse events."* The MHRA is unable to provide this information under section 1(3) of the Freedom of Information Act 2000.

   The MHRA assesses different endocrine disorders as separate safety signals. As such, a request for all internal risk assessments relating to endocrine adverse events would include a vast and wide range of disorders, ranging from, for example, Cushing's disease to menstrual disorders. To facilitate this request, we would therefore ask that you specify which endocrine disorder adverse events' internal risk assessments you would like us to provide.

4. You request *"Copies of internal deliberations where MHRA decided not to list thyroid conditions as adverse reactions in SmPC documentation."* The MHRA does not hold this information and is therefore unable to provide it as part of this response.

   The MHRA has no record of corresponding with the Department for Health and Social Care (DHSC) to deliberate inclusions of thyroid conditions as adverse reactions in SmPC documentation. Typically, in the scenario you present, we would only have contacted the DHSC if we were planning on taking regulatory action against an authorised Covid-19 vaccine due to an endocrine disorder, which we have not.

5. You then request *"Copies of internal deliberations where MHRA decided not to list thyroid conditions as adverse reactions in SmPC documentation."* The MHRA does not hold this information and is therefore unable to provide it as part of this response.

   The MHRA has no record of internal deliberations regarding a decision to include or not include 'thyroid conditions' as adverse reactions in the Summary of Product Characteristics (SmPC) for any of the Covid-19 vaccines.

6. Finally, you then request *"Any document that evaluates the adequacy of current post-marketing surveillance for endocrine disorders."* Again, the MHRA is unable to provide this information under section 1(3) of the Freedom of Information Act 2000.

   As explained at point 3 of this response, the MHRA assesses different endocrine disorders as separate safety signals. As such, to facilitate this request, we would therefore ask that you specify which endocrine disorders you refer to when requesting documentation evaluating the adequacy of post-marketing surveillance for certain suspected adverse reactions to a Covid-19 vaccine.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.
Website: ICO FOI and EIR complaints or telephone 0303 123 1113.

Re-use of our information
The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:
https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/